title: Highlights in Head and Neck Cancer.
authors.affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
authors.forename: Nicole G
authors.initials: NG
authors.lastname: Chau
authors.affiliation: Department of Radiation Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
authors.forename: Roy B
authors.initials: RB
authors.lastname: Tishler
authors.affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
authors.forename: Robert I
authors.initials: RI
authors.lastname: Haddad
mesh_terms: D000631:Aminopyridines / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis / Q000378:metabolism; D059248:Chemoradiotherapy; D002986:Clinical Trials as Topic; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods*; D009025:Morpholines / Q000627:therapeutic use; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D000081082:Phosphoinositide-3 Kinase Inhibitors; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors / Q000378:metabolism; D000077195:Squamous Cell Carcinoma of Head and Neck / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology
chemical_list: D000631:Aminopyridines; D061067:Antibodies, Monoclonal, Humanized; D014408:Biomarkers, Tumor; D004791:Enzyme Inhibitors; D009025:Morpholines; C571178:NVP-BKM120; C105992:PDCD1 protein, human; D000081082:Phosphoinositide-3 Kinase Inhibitors; D061026:Programmed Cell Death 1 Receptor; C582435:pembrolizumab